Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$423.09 USD

423.09
517,813

-4.11 (-0.96%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $423.39 +0.30 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Medpace (MEDP) closed the most recent trading day at $305.90, moving +2.54% from the previous trading session.

Zacks Equity Research

CON or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

Sanghamitra Saha headshot

Is Healthcare Losing the Status of Safe Haven? ETFs in Focus

by Sanghamitra Saha

Healthcare stocks face new risks under Trump, despite their usual defensive reputation.

Zacks Equity Research

CON or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 19.93% and 5.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elevance Health (ELV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?

by Zacks Equity Research

Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the latest trading session, Medpace (MEDP) closed at $290.10, marking a +1.04% move from the previous day.

Zacks Equity Research

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

CoDiagnostics (CODX) delivered earnings and revenue surprises of -5.88% and 60.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Medpace (MEDP) closed at $330.59 in the latest trading session, marking a +1.96% move from the prior day.

Zacks Equity Research

CON or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Medpace (MEDP) Stock Moves -1.04%: What You Should Know

by Zacks Equity Research

In the latest trading session, Medpace (MEDP) closed at $322.93, marking a -1.04% move from the previous day.

Zacks Equity Research

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

by Zacks Equity Research

CON vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Medpace (MEDP) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Medpace (MEDP) concluded the recent trading session at $324.13, signifying a +1.55% move from its prior day's close.

Zacks Equity Research

Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 23.57% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs

by Zacks Equity Research

MOH expects total membership to be at 5.9 million by 2025-end.

Zacks Equity Research

Cencora (COR) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 6.57% and 4.31%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Medpace (MEDP) stood at $343.38, denoting a -1.65% change from the preceding trading day.

Zacks Equity Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.